A survey of Chinese physicians' preference and clinical use of Upadacitinib

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400085646

Enrollment

Unknown

Registered

2024-06-14

Start date

2024-06-15

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease

Interventions

Physicians:No intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Practicing physician of western medicine 2. The scope of practice includes gastroenterology, general surgery and other related departments that may use UPA 3. Volunteer to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Working experience less than 1 year 2. Graduate and standardized training for residents

Design outcomes

Primary

Measure	Time frame
Treatment preferences;	—

Countries

China

Contacts

Public ContactQian Cao

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

caoq@zju.edu.cn+86 135 8870 6896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026